Document is current
Any future updates will be listed below
-
Authors
Woodworth, Joshua S. https://orcid.org/0000-0002-0771-9056
Contreras, Vanessa
Christensen, Dennis
Naninck, Thibaut https://orcid.org/0000-0002-6261-6412
Kahlaoui, Nidhal
Gallouët, Anne-Sophie
Langlois, Sébastien
Burban, Emma
Joly, Candie
Gros, Wesley
Dereuddre-Bosquet, Nathalie https://orcid.org/0000-0001-6682-6313
Morin, Julie
Liu Olsen, Ming
Rosenkrands, Ida https://orcid.org/0000-0003-0085-7883
Stein, Ann-Kathrin
Krøyer Wood, Grith
Follmann, Frank https://orcid.org/0000-0002-8373-7774
Lindenstrøm, Thomas https://orcid.org/0000-0002-7162-8124
Hu, Tu https://orcid.org/0000-0002-4635-4117
Le Grand, Roger https://orcid.org/0000-0002-4928-4484
Pedersen, Gabriel Kristian https://orcid.org/0000-0001-6872-3975
Mortensen, Rasmus https://orcid.org/0000-0003-0177-3032
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI135721)
- License Information
-
More Information
Article History
Received: 14 March 2024
Accepted: 24 September 2024
First Online: 17 October 2024
Competing interests
: JSW, GKP, DC and RM are co-inventors of a patent covering the use of CAF®10b and derivatives. All rights have been assigned to Statens Serum Institut (SSI). DC was employed by SSI during the time of the study, but is now employed by Croda Pharma that, among others, develops and produces immunostimulators, adjuvants and delivery systems for vaccines. The remaining authors declare no competing interests.
